1. Home
  2.  » 
  3. Biologics
  4.  » 
  5. Drug Substance
  6.  » Cell Line Development
Cell Line Development
GPEx® cell line development technology is a proven technology that generates high-performance, highly stable, production cell lines. Virtually any cDNA (mAb and multigenic applications) can be packaged into the GPEx® retrovector and used to insert your gene of interest into cells. To date, over 600 different mAb and mAb fusions and over 80 different recombinant proteins have been produced using the GPEx® system, with 120+ ongoing clinical trials utilizing therapeutic candidates developed using GPEx® technology and 12 commercially-approved products.

For those looking for high titer (up to 10 g/L for standard mAbs) and robust performance in CHO cells, GPEx® Boost combines two proven technologies for a synergistic effect on protein productivity. For those in non-CHO cells, original GPEx® technology enables high-performance and highly stable production cell lines in CHO, HEK293, PER.C6, CAP and a variety of other mammalian cells.

Back to top


GPEx® technology uses a retrovector technology that ensures the stable transduction of targeted cells, approaching 100% efficiency. This level of efficiency eliminates the requirement for selectable markers and stable clonal cell lines are produced rapidly. GPEx technology utilizes additional transductions to increase copy number or to add other complementary genes. Whether you are using GPEx® Boost or original GPEx® technology, you will enjoy many of the same advantages.
Back to top



  • Up to 7 g/L titer for standard mAbs
  • Stability demonstrated up to 100 generations. No need for selectable markers
  • Stable pools are generated from the outset and removes stability testing from the critical path.

Proven Technology

  • 12 commercially approved products use GPEx® technology
  • 120+ ongoing clinical trials with therapeutic candidates developed utilizing GPEx® technology
  • 600+ different antibodies/antibody fusions
  • 80+ different recombinant proteins
Back to top


Building on years of proven expertise, Catalent has further optimized its GPEx® cell line technology to develop GPEx® Boost, the next generation in cell line development. The technology combines Catalent’s proven GPEx® expression platform with the CHOZN® glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line* to improve the ability of cells to produce high titers and increase specific productivities of a protein of interest.


  • Up to 10 g/L titer for standard mAbs
  • Up to four-fold higher titers in difficult-to-express proteins
  • Reduced ammonia build up leading to improved cell growth and viability
  • Can be used with SMARTag® bioconjugation technology for development of antibody-drug conjugates (ADCs)
  • Commercially-approved and industry-accepted GPEx® and GS knock-out technologies
  • Same stability benefits as enjoyed with original GPEx® technology

Note: GPEx and SMARTag are registered trademarks of Catalent, Inc. or its affiliates or subsidiaries.

* Catalent has licensed the CHOZN® GS cell line from Merck KGaA, Darmstadt, Germany or its affiliates. CHOZN® is a registered trademark of Merck KGaA, Darmstadt, Germany or its affiliates.